Evidence of Monoamine Oxidase Inhibition by Myristicin and Nutmeg
- 1 March 1963
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 112 (3) , 647-650
- https://doi.org/10.3181/00379727-112-28128
Abstract
Summary Nutmeg and its active component, myristicin, show evidence of central monoamine oxidase (MAO) inhibition by their ability to lower the convulsive dose of intravenous tryptamine in mice and to increase rat brain 5-hydroxytryptamine concentrations. They also show some ability to antagonize reserpine-induced ptosis of the eyelids. Myristicin is chemically unique as a nitrogen-free MAO inhibitor. Although its potency in this respect is not comparable to some of the more potent inhibitors such as tranylcypromine and iproniazid, it seems quite adequate when compared to its low toxicity. Other volatile components of nutmeg such as borneol, geraniol and safrole, do not show tryptamine potentiation, although some appear to cause C.N.S. stimulation in high doses. Further study is recommended for more direct evidence of nutmeg and myristicin as enzyme inhibitors and for their utility as anti-depressant drugs.Keywords
This publication has 4 references indexed in Scilit:
- RELATIVE ACTIVITY OF SOME INHIBITORS OF MONO‐AMINE OXIDASE IN POTENTIATING THE ACTION OF TRYPTAMINE IN VITRO AND IN VIVOBritish Journal of Pharmacology and Chemotherapy, 1961
- BIOASSAY OF RAUWOLFIA-ROOTS AND ALKALOIDS1957
- IDENTIFICATION AND ASSAY OF SEROTONIN IN BRAIN1956
- A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS1949